The study of pharmacodynamics of a medicine based on humanized monoclonal antibodies against IL-17 in rabbit model of antigen-induced arthritis
Abstract
The present article contains scientific data on the assessment of specific activity of therapeutic humanized monoclonal antibodies against IL-17 in rabbit model of antigen-induced arthritis. Pharmacokinetics and immunogenicity of anti-IL-17A preparation have been studied. The severity of rheumatoid arthritis progression has been assessed by the levels of joint damage, the levels of inflammatory markers and according to Menkin histological grade.
About the Authors
A. A. Nedorubov
CJSC «BIOCAD»
Russian Federation
Senior researcher of the Department of preclinical trials of medicines
Russian Federation
Senior researcher of the Department of preclinical trials of medicines
A. V. Grachev
CJSC «BIOCAD»
Russian Federation
Senior researcher of the Department of immunochemistry
Russian Federation
Senior researcher of the Department of immunochemistry
M. A. Varavko
CJSC «BIOCAD»
Russian Federation
Senior researcher of the Department of preclinical trials of medicines
Russian Federation
Senior researcher of the Department of preclinical trials of medicines
E. L. Morozova
CJSC «BIOCAD»
Russian Federation
Head of the Department of preclinical trials of medicines
Russian Federation
Head of the Department of preclinical trials of medicines
References
1. Chew MWK, Hendersont B, Edwards JCW. Antigen-induced arthritis in the rabbit: ultrastructural changes at the chondrosynovial junction. Int J Exp Path. 1990; 71: 879–94.
2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903–11.
3. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85(3): 307–10.
4. Shabgah AG, Fattahi E, Shahneh FZ. Interleukin-17 in human inflammatory diseases. Postepy Dermatol Alergol. 2014; 31(4): 256–61.
5. Kologrivova IV, Kologrivov EN, Suslova TE. Molecular aspects of the functioning of T-helper 17-type. Bulleten sibirskoy meditsiny 2011; 10(4): 93–98 (in Russian).
6. Isailovic N, Daigo K, Mantovani A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015; 60: 1–11.
7. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatology 2015; 27(2): 127–33.
8. van den Berg WB, McInnesIB. Th17 cells and IL-17a–focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum. 2013; 43(2): 158–70.
9. Khan D, Ahmed SA. Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs. Front Genet. 2015; (6): 236.
10. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol. 2001; 167(2): 1004–13.
11. Oliveira PG, Grespan R, Pinto LG, Meurer L, Brenol JCT, Roesler R, Schwartsmann G, Cunha FQ, Xavier RM. Protective Effect of RC-3095, an Antagonist of the Gastrin-Releasing Peptide Receptor, in Experimental Arthritis. Arthritis & Rheumatism 2011; 63(10): 2956–65.
12. Link TM, ed. Cartilage Imaging. Significance, Techniques, and New Developments. New York: Springer Science+Business Media; 2011.
13. Van der Sluijs JA, Geesink RG, van der Linden AJ, Bulstra SK, Kuyer R, Drukker J. The reliability of the Mankin score for osteoarthritis. Journal of Orthopaedic Research 1992; 10(1): 58–61.
Review
For citations:
Nedorubov A.A., Grachev A.V., Varavko M.A., Morozova E.L. The study of pharmacodynamics of a medicine based on humanized monoclonal antibodies against IL-17 in rabbit model of antigen-induced arthritis. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(2):101-107. (In Russ.)
Views:
777
Email this article 